Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Demecarium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 17/20 | 0.69 |
| ▸ | BCHE | P06276 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demecarium SCHEMBL31649032 | 1.00 | ACHE (0.69) | ACHEBCHELMNAMEN1KMT2A | |
| Demecarium SCHEMBL34283 | 0.99 | ACHE (0.70) | ACHEBCHELMNAMEN1KMT2A | |
| Demecarium SCHEMBL29425243 | 0.99 | ACHE (0.70) | ACHEBCHELMNAMEN1KMT2A | |
| SCHEMBL12043598 | 0.86 | ACHE (0.73) | ACHEBCHELMNAMEN1KMT2A | |
| Demecarium SCHEMBL2253116 | 0.86 | ACHE (0.54) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL29603805 | 0.82 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL34419 | 0.82 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL8026154 | 0.82 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL16228482 | 0.81 | ACHE (0.97) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL41128 | 0.81 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2799 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | claimed |
| EP-4596049-A2 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| WO-2025133260-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | UNIVERSITÄT REGENSBURG, IN VERTRETUNG DES FREISTAATES BAYERN (DE) | 2025-06-26 | — | — | WO | claimed |
| EP-4574143-A1 | INHIBITORS OF PLASMODIA REMODELING ENZYMES | Universität Regensburg (DE) | 2025-06-25 | — | — | EP | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| EP-4302829-B1 | PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC (US) | 2025-05-21 | — | — | EP | claimed |
| US-20250090621-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-03-20 | — | — | US | claimed |
| EP-4512471-A2 | ACETYLCHOLINESTERASE INHIBITORS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS | Attillaps Holdings (US) | 2025-02-26 | — | — | EP | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-4931279-A | Sustained release formulation containing an ion-exchange resin | BAUSCH & LOMB INCORPORATED (US) | 1990-06-05 | — | — | US | claimed |
| EP-0301392-A1 | Pharmaceutical composition for intranasal administration comprising GH - Releasing hormone, a cholinergic agonist and in case a bile salt | Pierrel S.p.A. (IT) | 1989-02-01 | — | — | EP | claimed |
| US-4713244-A | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent | BAUSCH & LOMB INCORPORATED (US) | 1987-12-15 | — | — | US | claimed |
| US-4668506-A | Sustained-release formulation containing and amino acid polymer | BAUSCH & LOMB INCORPORATED (US) | 1987-05-26 | — | — | US | claimed |
| EP-0219207-A2 | Sustained-release formulation comprising a hydrophobic polymer system | BAUSCH & LOMB INCORPORATED (US) | 1987-04-22 | — | — | EP | claimed |
| EP-0219208-A2 | Substained-release formulation containing an amino acid polymer | BAUSCH & LOMB INCORPORATED (US) | 1987-04-22 | — | — | EP | claimed |
| EP-0212959-A2 | Sustained-release formulation containing an amin acid polymer with a lower alkyl (C1-C4) polar solvent | BAUSCH & LOMB INCORPORATED (US) | 1987-03-04 | — | — | EP | claimed |
| EP-0166724-A1 | COMPOSITION FOR TREATING PEDICULOSIS. | SOFT SHEEN PRODUCTS INC (US) | 1986-01-08 | — | — | EP | claimed |
| WO-1985002755-A1 | METHOD AND COMPOSITION FOR TREATING PEDICULOSIS | SOFT SHEEN PRODUCTS, INC. (US) | 1985-07-04 | — | — | WO | claimed |
| US-4439427-A | Method and composition for treating pediculosis | SOFT SHEEN PRODUCTS, INC. (US) | 1984-03-27 | — | — | US | claimed |